Drug · CHEMBL1663
Trials82
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 12 more rest on that reading alone and are shown because the trials' posted result groups or NLM's indexing of their papers name the drug. 26 more that Open Targets linked to it are not shown, since the release's checks do not confirm them.
1 to 20 of 82
Download this page as JSON| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT00625365 | A Prospective, Phase IV, Surveillance Registry Study to Evaluate the Safety of DEFINITY® in Clinical Practice | Phase 4 | 1,060 | 2011-01-14 | definity | Its name | ClinicalTrials.gov |
| NCT00730964 | A Prospective Surveillance Trial to Evaluate the Safety of Optison in Clinical Practice. | Phase 4 | 1,039 | 2012-06-12 | perflutren protein-type A microspheres | Its name | ClinicalTrials.gov |
| NCT00162370 | A Study of Stress Echocardiography in Post-Menopausal Women at Risk for Coronary Disease | Phase 4 | 400 | 2016-12-08 | perflutren lipid microsphere | Open Targets' reading, confirmed by the trial's result groups | ClinicalTrials.gov |
| NCT01490892 | Quantitative Subharmonic Breast Imaging | Phase 4 | 219 | 2020-01-13 | definity | Its name | ClinicalTrials.gov |
| NCT03719612 | DEF-315 Better Accuracy in Ejection Fraction (EF) Assessment With DEFINITY | Phase 3 | 160 | 2021-01-07 | definity | Its name | ClinicalTrials.gov |
| NCT03571672 | DEF-314 Better Accuracy in Ejection Fraction (EF) Assessment With DEFINITY | Phase 3 | 153 | 2020-12-17 | definity | Its name | ClinicalTrials.gov |
| NCT02764801 | Contrast-enhanced Ultrasound Evaluation of Chemoembolization | Phase 3 | 131 | 2023-09-21 | definity | Its name | ClinicalTrials.gov |
| NCT03199274 | Perflutren Protein-Type A Microspheres and Contrast-Enhanced Ultrasound in Improving Response to Radioembolization Therapy in Patients With Liver Cancer | Phase 2 | 104 | 2025-08-20 | perflutren protein-type A microspheres | Its name | ClinicalTrials.gov |
| NCT01721447 | Efficacy of Optison Echo Contrast to Detect Thrombus in Left Atrial Appendage | Phase 4 | 100 | 2019-06-04 | optison | Its name | ClinicalTrials.gov |
| NCT02684435 | Contrast-enhanced Ultrasound of the Kidney | Phase 2 | 63 | 2019-07-02 | perflutren lipid | Open Targets' reading, confirmed by the trial's result groups | ClinicalTrials.gov |
| NCT02967458 | Detection of High Grade Prostate Cancer With Subharmonic Ultrasound Imaging, A Pilot Study | Phase 2 | 55 | 2019-05-21 | perflutren lipid microsphere | Open Targets' reading, confirmed by the trial's result groups | ClinicalTrials.gov |
| NCT02440334 | Two and Three Dimensional Contrast-enhanced Ultrasound for Screening of Renal Cell Carcinoma Recurrence Following Cryoablation | Phase 2 | 53 | 2019-04-30 | optison | Its name | ClinicalTrials.gov |
| NCT01489176 | Regadenoson Real Time Perfusion Imaging Trial-Optison | Phase 3 | 50 | 2022-12-30 | optison | Its name | ClinicalTrials.gov |
| NCT02625428 | IRB 14-009240, Does CEUS Positively Influence Selection of Biopsy Sites When Evaluating Transplant Kidneys? | Phase 4 | 40 | 2020-03-02 | optison | Its name | ClinicalTrials.gov |
| NCT03740997 | Study to Determine Safety and Dosage of OPTISON in Pediatric Participants | Phase 4 | 39 | 2024-05-17 | optison | Its name | ClinicalTrials.gov |
| NCT02880137 | Real Time Myocardial Perfusion Echocardiography for Coronary Allograft Vasculopathy | Phase 4 | 36 | 2019-06-20 | perflutren lipid microsphere | Open Targets' reading, confirmed by the trial's result groups | ClinicalTrials.gov |
| NCT00918866 | A Study of Commercial DEFINITY® to Monitor the Effects of the Heart's Pulmonary Artery Pressure | Phase 4 | 32 | 2011-07-11 | definity | Its name | ClinicalTrials.gov |
| NCT02204917 | CeVUS With Intravesical Administration of OPTISON TM (Trademark) in Children | Phase 1/2 | 31 | 2018-11-27 | optison | Its name | ClinicalTrials.gov |
| NCT00878878 | Evaluate Effect of Optison on Pulmonary Artery Systolic Pressure (PASP) and Pulmonary Vascular Resistance (PVR). | Phase 4 | 30 | 2012-08-24 | perflutren protein-type a microspheres | Its name | ClinicalTrials.gov |
| NCT04136912 | 3-D Super Resolution Ultrasound Microvascular Imaging | Phase 2 | 27 | 2025-09-15 | definity | Its name | ClinicalTrials.gov |
pipelines-2026-09-18-0.3.1
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL1663/trials